A biodegradable filler can leave the factory with a complete set of particle-size, morphology, molecular-weight, rheology, and initial biocompatibility data. Once implanted, however, the material does not remain at Day 0.
Water enters the material, polymer chains begin to break, and particle surfaces and internal structures change. As degradation products are released, local pH, ionic composition, and oxidative stress may also shift. Macrophages, fibroblasts, vascular cells, and the extracellular matrix respond to these changes over time.
For a material intended to remain in tissue for months, evaluation should therefore address both its initial state and the local environment it creates during degradation. This evolving material–tissue interface can be described as the degradation microenvironment.
Sterile Inflammation Is Not Infection
Sterile inflammation is an inflammatory process that occurs without confirmed microbial infection and may involve tissue injury, material surfaces, degradation products, and the host immune response. It is not the same as infection, and local erythema, induration, or material type alone cannot distinguish the two clinically.
Inflammation after implantation does not automatically indicate material failure. Macrophage recruitment, fibroblast activation, and matrix turnover are part of foreign-body responses and tissue remodeling. The important questions are how intense the response becomes, how long it persists, and whether it resolves toward stable remodeling or continues as chronic stimulation and tissue injury.
Those outcomes cannot be inferred from starting composition or a single cytotoxicity assay alone. Initial tests describe the material at the test starting point; sterile inflammation reflects a time-dependent interaction between material change and host response.
Degradation Begins Before Mass Is Lost
In polylactic-acid-based materials, ester bonds in the polymer backbone hydrolyze after water enters the matrix. Molecular weight can fall before the particle visibly changes or loses substantial mass. A 2023 study of medical-grade PLA/HAp films, for example, detected internal changes in glass-transition behavior before pronounced mass loss.
Further chain scission increases low-molecular-weight species and carboxyl end groups. If acidic products are generated faster than they diffuse or are cleared, the particle interior or material–tissue interface may develop a chemical environment that differs from the surrounding fluid and can influence subsequent hydrolysis.
| Time point | What to assess | What it cannot establish alone |
|---|---|---|
| Before implantation | Composition, molecular weight, particle size, morphology, rheology, and purity | The state of the material weeks or months later |
| During degradation | Molecular weight, mass, particle integrity, pH, ions, and degradation-product release | How host tissue responds |
| Host response | Macrophage state, ROS, cytokines, vascular response, and matrix turnover | Which individual raw material caused the response |
pH and ROS Are Related but Distinct
Polylactic acid degradation produces acidic species, but local acidification is not determined by acid generation alone. Polymer molecular weight, particle dimensions, porosity, water uptake, diffusion distance, and the buffering and clearance capacity of surrounding fluid all influence the result.
The pH measured after immersing a sample in a large volume of PBS is also not identical to the local pH inside a microsphere or at its tissue interface. A small change in bulk medium does not exclude molecular-weight loss or acidic-product accumulation within the material.
Reactive oxygen species represent a separate dimension. Oxidative stress may interact with inflammatory mediators, cell state, and matrix metalloproteinases, but reducing acidification does not automatically resolve every oxidative or inflammatory pathway. In a 2024 PDLLA study using UVB-stressed cells and animal skin, investigators observed changes in NLRP3-related components, MMP2, and MMP9. Those findings remain specific to the photodamage model used.
HAp Can Change Degradation, but Not in One Fixed Direction
Hydroxyapatite (HAp) has long been incorporated into polylactic-acid-based composites. In a 1997 in vitro PLA-PGA study, calcium hydroxyapatite and other inorganic components altered the fall in test-medium pH. That result should not be reduced to the claim that adding HAp will always neutralize degrading polylactic acid.
Within a composite, HAp may affect water uptake, interfacial structure, porosity, dissolution, and ion exchange at the same time. Published degradation results also point in different directions. In 2023 PLA/HAp films, higher HAp content slowed later hydrolysis. In an in vitro study by Popkov and colleagues, higher HAp loading in PLLA/HAp implant materials was associated with greater PLLA hydrolysis and more calcium and phosphate release.
The polymer, HAp source, loading, geometry, and test method differed between those studies, so their results are not directly contradictory. Together, they show that the effect of HAp belongs to the complete composite structure rather than following a fixed direction independent of formulation and geometry.
What Did the 2026 Composite Microsphere Study Show?
In August 2026, Applied Materials Today published a material, cell, and animal study of composite microspheres made from PDLLA, HAp, and D-α-tocopherol acetate (α-TA). The approximately 30–70 μm microspheres were combined with CMC to create an injectable formulation designated CMC@PDLLA/HAp(α-TA).
The design addressed two variables. HAp was incorporated to modify the degradation-associated environment, while α-TA served as an antioxidant component. The paper reported sustained α-TA release for at least six weeks. In the cell and animal models used, the investigators observed lower ROS and inflammatory mediators together with more prolonged, orderly collagen deposition.
These findings cannot be separated into a claim that HAp alone has a clinical anti-inflammatory effect. The evaluated material was a complete PDLLA/HAp/α-TA/CMC system, and the study did not include human clinical data. The difference between HAp starting material below 100 nm and formed microspheres around 30–70 μm also illustrates why powder, formed particles, and finished formulations are different material levels.
Lower Inflammation and More Collagen Are Not Standalone Endpoints
Regenerative materials are not designed simply to suppress every inflammatory signal. Transient immune-cell participation can support remodeling; the concern is a response that remains dysregulated over time. Immune inertness and immune modulation that supports organized repair are not equivalent goals.
In a 2023 aged-animal-skin study, Oh and colleagues linked PDLLA-associated matrix changes with macrophage and adipose-derived stem-cell responses. The finding remains specific to that animal model and does not establish inflammation duration or tissue-remodeling outcomes in humans.
Collagen findings also require context. Stained area, collagen-related mRNA, deposited protein, collagen subtype, and fiber organization are different endpoints. An increase in collagen accompanied by persistent inflammatory-cell infiltration would not have the same biological meaning as stable, organized matrix formation.
A 2026 short-term in vitro comparison of commercial biostimulatory fillers found product-specific differences in collagen-related gene expression and macrophage cytokine profiles. It did not evaluate collagen-fiber organization, the duration of inflammation, or macrophage states in vivo, so it cannot establish comparative long-term remodeling or clinical outcomes.
What Should a Dynamic Evaluation Measure?
For degradable composite microspheres, the initial certificate of analysis remains important, but it describes only the starting point. A more complete development program connects material change, biological response, and formulation attribution along the same timeline.
| Evaluation dimension | Questions to address |
|---|---|
| Material degradation | When does molecular weight fall, when is mass lost, and when do particles crack, collapse, or fragment? |
| Local environment | How do bulk and local pH, ions, degradation products, and ROS change by degradation stage? |
| Tissue response | Do macrophage, fibroblast, vascular, and matrix responses follow a coherent time course? |
| Formulation attribution | What changes after adding the polymer, HAp, antioxidant, or carrier, and are suitable controls included? |
For HAp composites, phase composition, Ca/P, and particle size remain foundational. Once HAp enters a polymer matrix, dispersion, interface structure, dissolution in acidic conditions, ion release, and batch reproducibility become additional questions. Our earlier discussion of sterilization stability follows the same principle: acceptable starting data do not guarantee that a material remains unchanged after later processing.
Adding time to material evaluation is not the same as adding a longer checklist. Each measurement should correspond to a defined stage. Day 0 establishes the starting point; Week 2, Week 6, or Month 3 shows how the material changes in a tissue-like environment and whether that evolution remains compatible with the intended remodeling process.
Technical review: Nanjing Junzhuo Materials Technology Team. This article discusses material-science and experimental evidence concerning biodegradable soft-tissue fillers. Cell and animal findings do not establish clinical outcomes, and sterile inflammation cannot be diagnosed from material type or local signs alone. Findings from HAp composite systems do not apply directly to isolated HAp/CaHA powder or other finished formulations.
References
- Zhan S, Gao C, Yan J, et al. D-α-tocopherol acetate and hydroxyapatite composite poly(D,L-lactic acid) microspheres suppress sterile inflammation by improving microenvironment. Applied Materials Today. 2026;51:103305. DOI: 10.1016/j.apmt.2026.103305.
- Agrawal CM, Athanasiou KA. Technique to control pH in vicinity of biodegrading PLA-PGA implants. Journal of Biomedical Materials Research. 1997;38(2):105–114. DOI: 10.1002/(SICI)1097-4636(199722)38:2<105::AID-JBM4>3.0.CO;2-U.
- Bauer L, Rogina A, Ivanković M, Ivanković H. Medical-Grade Poly(Lactic Acid)/Hydroxyapatite Composite Films: Thermal and In Vitro Degradation Properties. Polymers. 2023;15(6):1512. DOI: 10.3390/polym15061512.
- Popkov AV, Stogov MV, Gorbach EN, et al. Hydrolysis of Bone-Replacing Materials Based on Polylactic Acid and Containing Hydroxyapatite in an In Vitro Experiment. Bulletin of Experimental Biology and Medicine. 2022. DOI: 10.1007/s10517-022-05656-3.
- Oh S, Seo SB, Kim G, et al. Poly-D,L-Lactic Acid Filler Increases Extracellular Matrix by Modulating Macrophages and Adipose-Derived Stem Cells in Aged Animal Skin. Antioxidants. 2023;12(6):1204. DOI: 10.3390/antiox12061204.
- Byun KA, Seo SB, Oh S, et al. Poly-D,L-Lactic Acid Filler Attenuates Ultraviolet B-Induced Skin Pigmentation by Reducing Destruction of the Basement Membrane. International Journal of Molecular Sciences. 2024;25(21):11568. DOI: 10.3390/ijms252111568.
- Min S, Han G, Kim J. Comparative Characterization of Injectable Dermal Fillers: Physicochemical Properties, Cytotoxicity, Collagen-Stimulating Activity, and Macrophage Cytokine Profiles. Cosmetics. 2026;13(4):188. DOI: 10.3390/cosmetics13040188.